Drug intelligence / Profile preview

OGFT-001

Development stage: Unknown
Lead developer: Orca Biosystems
Modality: Cell Therapies
Administration: Intravenous

Overview

**OGFT-001** is a fully controlled allogeneic cell therapy product developed by Orca Bio, featuring a next-generation formulation of T cells designed as a replacement for conventional bone marrow transplants (BMTs) in hematologic malignancies. It aims to deliver curative outcomes with reduced toxicity, particularly graft-versus-host disease (GVHD), by precisely engineering donor-derived immune cells for better control of alloreactive responses while preserving graft-versus-tumor effects.[3][5][7]

Beyond the preview

Go deeper on OGFT-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OGFT-001.

Explore the full profile